Aldo-keto reductase family 1 member C3 (AKR1C3) Is a biomarker and therapeutic target for castration-resistant prostate cancer

Molecular Medicine

Volumn 18, Issue 11, 2012, Pages 1449-1455

  Hamid, Agus Rizal A H ^a,b,c,d   Pfeiffer, Minja J ^a,d   Verhaegh, Gerald W ^a,d   Schaafsma, Ewout ^a   Brandt, Andre ^a   Sweep, Fred C G J ^a   Sedelaar, John P M ^a   Schalken, Jack A ^a,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER C3; CASPASE 3; CASPASE 7; INDOMETACIN; PRASTERONE; TUMOR MARKER; UNCLASSIFIED DRUG;

ALDO KETO REDUCTASE FAMILY 1 MEMBER C3 GENE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; STEROIDOGENESIS; UPREGULATION; VALIDATION PROCESS; WESTERN BLOTTING;

3-HYDROXYSTEROID DEHYDROGENASES; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INDOMETHACIN; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872226067     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00296     Document Type: Article

References (37)

1. Lee DJ, et al. (2012) Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int. 109:968-85.
2. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. (2012). Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 110:1580-8.
3. Aggarwal R, Ryan CJ. (2011) Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 16:264-75.
4. Mottet N, et al. (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59:572-83.
5. Nishiyama T, Hashimoto Y, Takahashi K. (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 10:7121-6.
6. Mohler JL, et al. (2004) The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10:440-8.
7. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11:4653-7.
8. Hofland J, et al. (2010) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 70:1256-64.
9. Locke JA, et al. (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68:6407-15.
10. Montgomery RB, et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68:4447-54.
11. Stanbrough M, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66:2815-25.
12. Mizokami A, et al. (2009) Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydro-epiandrosterone. Endocr. Relat. Cancer. 16:1139-55.
13. Tran C, et al. (2009) Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science. 324:787-90.
14. Attard G, Reid AH, Olmos D, de Bono JS. (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69:4937-40.
15. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol. Med. 17:657-64.
16. De Kok JB, et al. (2005) Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab. Invest. 85:154-9.
17. Pfaffl MW. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
18. Azzarello J, Fung KM, Lin HK. (2008) Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J. Histochem. Cytochem. 56:853-1.
19. Kogan I, et al. (2006) hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res. 66:3531-40.
20. Pfeiffer MJ, Mulders PF, Schalken JA. (2010) An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate. 70:1524-32.
21. Klein KA, et al. (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 3:402-8.
22. Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K. (2007) The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J. Urol. 178:1282-8.
23. Swinkels LM, Ross HA, Smals AG, Benraad TJ. (1990) Concentrations of total and free dehydroepiandrosterone in plasma and dehydroepiandrosterone in saliva of normal and hirsute women under basal conditions and during administration of dexamethasone/synthetic corticotropin. Clin. Chem. 36:2042-6.
24. Swinkels LM, van Hoof HJ, Ross HA, Smals AG, Benraad TJ. (1992) Low ratio of androstenedione to testosterone in plasma and saliva of hirsute women. Clin. Chem. 38:1819-23.
25. Swinkels LM, van Hoof HJ, Ross HA, Smals AG, Benraad TJ. (1991) Concentrations of salivary testosterone and plasma total, non-sex-hormonebinding globulin-bound, and free testosterone in normal and hirsute women during administration of dexamethasone/synthetic corticotropin. Clin. Chem. 37:180-5.
26. Byrns MC, Steckelbroeck S, Penning TM. (2008) An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75:484-93.
27. Sedelaar JP, Isaacs JT. (2009) Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate. 69:1724-9.
28. van Bokhoven A, et al. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate. 57:205-25.
29. Byrns MC, Mindnich R, Duan L, Penning TM. (2012) Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride. J. Steroid. Biochem. Mol. Biol. 130:7-15.
30. Wlodkowic D, Skommer J, Darzynkiewicz Z. (2012) Cytometry of apoptosis: historical perspective and new advances. Exp. Oncol. 34:255-62.
31. Wako K, et al. (2008) Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J. Clin. Pathol. 61:448-54.
32. Kohli M, Tindall DJ. (2010) New developments in the medical management of prostate cancer. Mayo Clin. Proc. 85:77-86.
33. Adeniji AO, et al. (2012) Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J. Med. Chem. 55:2311-23.
34. Brozic P, et al. (2012) Selective inhibitors of aldoketo reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. J. Med. Chem. 55:7417-24.
35. Chen M, et al. (2012) Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist: therapeutic leads for castrate resistant prostate cancer. Bioorg. Med. Chem. Lett. 22:3492-7.
36. Jamieson SM, et al. (2012) 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly potent and selective inhibitors of the type 5 17-beta-hydroxysteroid dehydrogenase AKR1C3. J. Med. Chem. 55:7746-58.
37. Attard G, et al. (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate